Clinical trialNCT01933815SuspendedPhase 1/PHASE2Interventional

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

SponsorCortice Biosciences, Inc.Enrollment92Glioblastoma Multiforme

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial is divided into two parts, a dose-escalation study (phase 1) and a randomized study (phase 2). The purpose of the dose-escalation study (phase 1) is to determine the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation therapy and temozolomide (TMZ). The purpose of the randomized study (phase 2) is to determine the safety and efficacy of the phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects who have GBM that has progressed following prior radiation therapy and TMZ.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

J. P. Duic, M.D.
The Long Island Brain Tumor Center at Neurological Surgery, P.C.
Principal Investigator
clinicaltrials.gov ↗
Jian Campian, M.D.
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗
Louis B. Nabors, III, M.D.
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗
Nimish Mohile, M.D.
University of Rochester
Principal Investigator
clinicaltrials.gov ↗
Pierre Giglio, M.D.
Ohio State University
Principal Investigator
clinicaltrials.gov ↗
Samuel A. Goldlust, M.D.
John Theurer Cancer Center at Hackensack University Medical Center
Principal Investigator
clinicaltrials.gov ↗
Sigmund Hsu, M.D.
Memorial Hermann Hospital
Principal Investigator
clinicaltrials.gov ↗
Tara L. Benkers, M.D.
Swedish Neuroscience Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Washington University School of Medicine
St Louis, Missouri, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
the Long Island Brain Tumor Center at Neurological Surgery, P.C.
Commack, New York, United States
the Long Island Brain Tumor Center at Neurological Surgery, P.C.
Lake Success, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Memorial Hermann Hospital
Houston, Texas, United States
Swedish Neuroscience Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →TPI-287

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2013
Primary completion: 30 Nov 2024
Completion: 31 May 2025
Last update posted: 22 Feb 2023
Registered enrollment: 92
Registry id: NCT01933815

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.